Published in J Clin Invest on November 01, 2001
Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J (2003) 11.27
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2006) 4.92
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A (2002) 2.69
Leukaemogenesis: more than mutant genes. Nat Rev Cancer (2010) 2.16
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A (2005) 2.07
An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A (2003) 1.69
Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol (2002) 1.64
Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol (2010) 1.55
Assembly of the SMRT-histone deacetylase 3 repression complex requires the TCP-1 ring complex. Genes Dev (2002) 1.53
One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett (2013) 1.49
The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer (2003) 1.48
Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis (2005) 1.46
The APL paradigm and the "co-clinical trial" project. Cancer Discov (2011) 1.33
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A (2008) 1.27
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs (2010) 1.27
Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol Cell Biol (2004) 1.26
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci U S A (2007) 1.26
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med (2013) 1.15
Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples. Proc Natl Acad Sci U S A (2010) 1.15
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate. Blood (2010) 1.12
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther (2008) 1.11
Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev (2009) 1.10
Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One (2011) 1.05
A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica (2009) 1.04
In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med (2002) 1.04
Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia (2013) 1.00
Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol (2007) 0.99
Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer (2006) 0.96
Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. AIDS (2013) 0.94
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica (2010) 0.94
The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther (2010) 0.93
Inhibition of the NAD-dependent protein deacetylase SIRT2 induces granulocytic differentiation in human leukemia cells. PLoS One (2013) 0.92
Unlocking the potential of retinoic acid in anticancer therapy. Br J Cancer (2014) 0.90
The role of HDACs inhibitors in childhood and adolescence acute leukemias. J Biomed Biotechnol (2011) 0.88
Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. Biologics (2007) 0.88
Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer. J Transl Med (2011) 0.84
Effects of PPARγ Ligands on Leukemia. PPAR Res (2012) 0.84
Designed transcription factors as structural, functional and therapeutic probes of chromatin in vivo. Fourth in review series on chromatin dynamics. EMBO Rep (2002) 0.84
Epigenetics in the hematologic malignancies. Haematologica (2014) 0.83
The recognition of N-glycans by the lectin ArtinM mediates cell death of a human myeloid leukemia cell line. PLoS One (2011) 0.82
pp32 reduction induces differentiation of TSU-Pr1 cells. Am J Pathol (2004) 0.82
Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy. Antioxid Redox Signal (2014) 0.82
Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a TRAnsition to targeted therapies. Br J Cancer (2014) 0.82
INK4 Family -A promising target for 'gene-regulating chemoprevention' and 'molecular-targeting prevention' of cancer. Environ Health Prev Med (2005) 0.81
Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells. Br J Cancer (2014) 0.79
Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development. Leukemia (2015) 0.78
Targeting aberrant transcriptional repression in leukemia: a therapeutic reality? J Clin Invest (2001) 0.78
Strategies to modulate heritable epigenetic defects in cellular machinery: lessons from nature. Pharmaceuticals (Basel) (2012) 0.78
Dual regulation of P-glycoprotein expression by trichostatin A in cancer cell lines. BMC Mol Biol (2012) 0.78
The DAC system and associations with acute leukemias and myelodysplastic syndromes. Invest New Drugs (2010) 0.77
Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms. Mol Med Rep (2015) 0.77
Vorinostat-An Overview. Indian J Dermatol (2015) 0.77
Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells. Oxid Med Cell Longev (2014) 0.77
ATOH1 Can Regulate the Tumorigenicity of Gastric Cancer Cells by Inducing the Differentiation of Cancer Stem Cells. PLoS One (2015) 0.76
An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts. Cell Death Dis (2016) 0.76
Promyelocytic leukemia zinc finger-retinoic acid receptor α (PLZF-RARα), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes. J Biol Chem (2014) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A (1999) 39.79
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods (1995) 16.00
Histone acetylation in chromatin structure and transcription. Nature (1997) 14.64
A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (1997) 9.71
A decade of molecular biology of retinoic acid receptors. FASEB J (1996) 9.70
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell (1991) 9.40
The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell (1991) 8.98
Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (1998) 8.75
Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature (1997) 7.66
Rb interacts with histone deacetylase to repress transcription. Cell (1998) 7.22
Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature (1998) 6.87
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med (1998) 6.83
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst (2000) 5.21
Acute promyelocytic leukemia. N Engl J Med (1993) 4.63
The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr (1996) 4.62
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood (1999) 4.58
Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays (1995) 4.43
Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem (1982) 4.04
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A (1998) 3.62
ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A (1998) 3.59
Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science (1991) 3.57
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med (1991) 3.52
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A (1999) 3.26
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol (1998) 3.13
Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet (1998) 2.97
Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene (1991) 2.86
Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci U S A (1997) 2.82
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst (1998) 2.64
Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci U S A (1996) 2.48
Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A (1997) 2.47
Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood (1994) 2.38
Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem (1999) 2.14
The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood (1996) 1.98
Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J (1995) 1.94
FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res (1998) 1.78
Retinoids in cancer therapy. J Clin Oncol (1992) 1.59
Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood (1995) 1.58
Unliganded thyroid hormone receptor alpha can target TATA-binding protein for transcriptional repression. Mol Cell Biol (1996) 1.57
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A (2000) 1.57
Transcription therapy for cancer. Oncogene (2001) 1.40
Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. J Clin Invest (1993) 1.36
Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res (2000) 1.36
Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet (1997) 1.34
Two critical hits for promyelocytic leukemia. Mol Cell (2000) 1.33
Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res (2001) 1.33
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene (1999) 1.22
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood (1998) 1.20
The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet (1999) 1.18
Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-erbA yields a chromatin infrastructure-dependent transcriptional repression pathway. EMBO J (2000) 1.18
In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene (1999) 1.04
Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase. Blood (1996) 0.98
Arsenic and apoptosis in the treatment of acute promyelocytic leukemia. J Natl Cancer Inst (1998) 0.96
Avian erythroleukemia: a model for corepressor function in cancer. Oncogene (2001) 0.88
Molecular mechanisms of corepressor function. Curr Top Microbiol Immunol (2001) 0.85
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell (1991) 9.40
Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12
CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem (2010) 8.79
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature (1999) 7.85
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 7.47
Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med (1998) 6.83
The multiple roles of PTEN in tumor suppression. Cell (2000) 6.71
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet (2001) 5.92
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet (1997) 5.55
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A (2000) 5.53
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst (2000) 5.21
Erythroleukemic differentiation. Annu Rev Biochem (1978) 5.19
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90
Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol (1999) 4.42
The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene (2008) 4.39
ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell (2001) 4.38
Impaired Fas response and autoimmunity in Pten+/- mice. Science (1999) 4.25
Role of SUMO-1-modified PML in nuclear body formation. Blood (2000) 4.05
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A (2004) 3.86
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Role of PML in cell growth and the retinoic acid pathway. Science (1998) 3.82
The transcriptional role of PML and the nuclear body. Nat Cell Biol (2000) 3.80
PML is essential for multiple apoptotic pathways. Nat Genet (1998) 3.75
A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc Natl Acad Sci U S A (1976) 3.70
Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med (2001) 3.62
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A (1998) 3.62
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol (2001) 3.24
In vitro synthesis of DNA components of human genes for globins. Nat New Biol (1972) 3.23
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.20
The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med (1992) 2.99
Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet (1998) 2.97
Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol (2001) 2.91
The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene (1995) 2.80
Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med (1990) 2.76
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A (1996) 2.72
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst (1998) 2.64
Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds. Proc Natl Acad Sci U S A (1975) 2.60
BCL-6 regulates chemokine gene transcription in macrophages. Nat Immunol (2000) 2.58
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol (2000) 2.58
Increased efficiency of exogenous messenger RNA translation in a Krebs ascites cell lysate. Proc Natl Acad Sci U S A (1972) 2.49
Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A (1997) 2.47
Erythropoietic differentiation in colonies of cells transformed by Friend virus. Proc Natl Acad Sci U S A (1974) 2.47
Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J (2000) 2.38
Effect of hexamethylene bisacetamide on the commitment to differentiation of murine erythroleukemia cells. Cancer Res (1977) 2.26
The function of PML in p53-dependent apoptosis. Nat Cell Biol (2000) 2.24
Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci U S A (2001) 2.19
Plzf regulates limb and axial skeletal patterning. Nat Genet (2000) 2.14
Induction of erythroid differentiation by dimethylsulfoxide in cells infected with Friend virus: relationship to the cell cycle. Proc Natl Acad Sci U S A (1975) 2.12
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A (2008) 2.10
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
Acute promyelocytic leukemia: from genetics to treatment. Blood (1994) 2.09
Tumor promoters inhibit spontaneous and induced differentiation of murine erythroleukemia cells in culture. Proc Natl Acad Sci U S A (1977) 2.09
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res (2001) 2.08
Decreased globin messenger RNA in thalassemia detected by molecular hybridization. Proc Natl Acad Sci U S A (1973) 2.07
Polyribosome dissociation and formation in intact reticulocytes with conservation of messenger ribonucleic acid. Proc Natl Acad Sci U S A (1965) 2.06
All-trans-retinoic acid: what is it good for? J Clin Oncol (1992) 2.03
Erythroid cell differentiation: murine erythroleukemia cell variant with unique pattern of induction by polar compounds. Proc Natl Acad Sci U S A (1976) 1.99
Changes in gene expression associated with induced differentiation of erythroleukemia: protooncogenes, globin genes, and cell division. Proc Natl Acad Sci U S A (1986) 1.99
Relative numbers of human globin genes assayed with purified alpha and beta complementary human DNA. Proc Natl Acad Sci U S A (1975) 1.97
A role for PML and the nuclear body in genomic stability. Oncogene (1999) 1.97
The theory of APL revisited. Curr Top Microbiol Immunol (2007) 1.96
Abnormal or absent beta mRNA in betao Ferrara and gene deletion in delta beta thalassaemia. Nature (1976) 1.96
Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of iepsilon transcription and immunoglobulin E switching. Mol Cell Biol (1999) 1.91
Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci U S A (1991) 1.90
Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion. J Clin Invest (1997) 1.86
Evidence for BLM and Topoisomerase IIIalpha interaction in genomic stability. Hum Mol Genet (2001) 1.85
RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell (1999) 1.85
A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat Genet (1999) 1.78
Murine erythroleukemia cell differentiation: DNase I hypersensitivity and DNA methylation near the globin genes. Proc Natl Acad Sci U S A (1982) 1.77